Tirzepatide has a four-week contraceptive precaution after starting and each dose increase. Semaglutide guidance differs; vomiting and missed pills need separate care.
Tirzepatide may reduce the effectiveness of oral hormonal contraception. The US Zepbound label advises switching to a non-oral contraceptive method or adding a barrier method for four weeks after starting treatment and for four weeks after every dose increase. Do not wait for nausea or vomiting before following that precaution. Zepbound prescribing information, revised August 2026
Semaglutide has different guidance. The UK's Faculty of Sexual and Reproductive Healthcare, now the College of Sexual and Reproductive Healthcare, does not recommend adding a barrier method solely because someone uses semaglutide. Vomiting, severe diarrhea and missed pills still need separate attention. FSRH clinical statement
Use the name and formulation on your prescription when discussing this with your pharmacist or prescriber. This guide concerns prescribed medicines; it does not provide a contraceptive plan for unapproved research products.
Tirzepatide slows stomach emptying, which can affect the absorption of medicines taken by mouth. The Zepbound label describes this effect as greatest after the first dose and diminishing with time. In its interaction study, a single 5 mg dose reduced exposure to the tested combined pill's components. These are drug-concentration findings, not a measured pregnancy rate or a percentage reduction in contraceptive protection. Label sections 7.2, 8.3 and 12.3
The four-week precaution applies after initiation as well as each dose escalation. If you switch from another GLP-1 medicine to tirzepatide, FSRH's patient guidance also advises backup for four weeks after the switch and after subsequent increases, while continuing oral contraception. Its alternative is a non-oral method. Patient leaflet, February 2025
Ask for the start and end dates of your precaution in writing. If another increase occurs before an earlier precaution has finished, have the pharmacist check the dates together. Taking the pill at a different time of day is not the replacement precaution specified in the label.
A 2015 study enrolled 43 postmenopausal women with type 2 diabetes; 39 completed it. Researchers compared exposure to ethinylestradiol and levonorgestrel before semaglutide and during steady-state treatment with a weekly 1 mg injection. The study did not find reduced bioavailability of either contraceptive component. The pharmacokinetic analyses included 37 women for ethinylestradiol and 40 for levonorgestrel. Original study
This was a small, open-label drug-interaction study sponsored by Novo Nordisk. It measured blood concentrations in a specific population, formulation and regimen, rather than pregnancies among people using contraception. It should not be described as proof that every GLP-1 product and every pill combination has been tested.
Current professional guidance incorporates those limitations. Keep the two questions separate: whether the medicine changes pill exposure, and whether illness or missed doses prevent your pill from being taken and absorbed correctly.
If you vomit soon after taking a contraceptive pill, or have severe diarrhea, follow that pill's missed-dose instructions and contact a pharmacist if you are unsure. The FSRH clinical statement directs readers to the manufacturer's instructions for vomiting within a few hours of pill taking, and flags severe diarrhea lasting more than 24 hours. Persistent symptoms warrant a discussion about non-oral contraception and condom use. Do not assume semaglutide's interaction guidance removes this separate problem. FSRH recommendations
Methods such as an IUD, implant, injection, patch or vaginal ring do not depend on absorption from the stomach. FSRH does not call for additional precautions for a GLP-1 interaction with these methods. However, starting or changing contraception has its own instructions. Some methods do not protect immediately, so confirm how to make the transition without a gap. Patient leaflet, MHRA advice
Contact a pharmacist or sexual-health service promptly about emergency contraception. Tell them the GLP-1 medicine, your contraceptive method, the dates of unprotected sex and any vomiting, diarrhea or missed pills. Do not delay while trying to calculate a risk from the drug-interaction percentages.
FSRH says direct evidence about GLP-1 medicines and oral emergency contraception is lacking. It identifies the copper IUD as the most effective emergency method and an option unaffected by vomiting or diarrhea. A clinician should assess which option is suitable and available in time; do not assume an oral emergency option is ineffective. Patient leaflet, emergency contraception section
The backup-contraception interval after a tirzepatide dose change is not the same as the interval before trying to conceive. Current UK MHRA guidance gives at least one month after stopping tirzepatide and at least two months after stopping semaglutide. Confirm a plan against your own product information and treatment needs, including diabetes care. If you think you are pregnant, contact your healthcare professional straight away. MHRA pregnancy guidance
Bring your medicine and pill names, start date, latest dose-increase date and symptoms to the appointment. For a different preparation question, see GLP-1 medicines before surgery; surgery instructions do not replace contraceptive advice.
Powered by BTST